1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Hugel, Inc.

Hugel, Inc.

KKRX:145020
180,100.00
KRW
-700.00
(-0.39%)
14,769.47EPS
18.18P/E
2.85TMarket Cap
Nov 16Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,231.23
10,233
15,103.3
19,446.54
18,259.73
5,520.5
17,100.74
19,008.93
23,636.77
28,223.95
34,389.4
39,414.3
44,090
Basic EPS, GAAP
2,356.72
5,336.07
5,262.59
7,777.86
6,981.5
1,203.91
3,402.68
4,733
4,811
8,217
12,520
13,061
14,523.8
Free Cash Flow per Basic Share
679.02
1,047.09
3,532.84
6,083.75
4,912.63
1,311.91
2,360.79
3,077.59
2,987.17
6,811.03
10,669.86
11,175.55
12,766.44
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.35
- -
- -
- -
Book Value per Share
5,189.57
25,276.37
30,927
64,534.38
68,720.22
56,672.9
60,495.25
63,859.92
67,095.45
68,346.51
74,667.88
87,960.16
97,674.9
Tangible Book Value per Share
5,070.7
17,455.89
23,111.29
58,626.93
58,099
45,848.9
46,737.85
47,635.52
50,147.94
51,674.01
56,467.61
70,251.24
78,957.21
Basic Weighted Avg Shares
6
6
8
9
10
37
12
12
12
11
11
11
11
Sales/Revenue/Turnover
40,350
65,066
124,189
182,085
182,392
204,568
211,038
231,859
281,675
319,700
373,047
425,110
479,572
Operating Margin (%)
38.38
27.29
50.94
55.98
33.21
33.28
36.99
41.24
35.99
36.84
44.56
47.25
43.56
Depreciation Expense
608
1,550
4,809
6,762
7,491
9,486
10,704
14,299
13,994
13,860
15,036
19,746
21,069
Net Income, GAAP
13,150
33,929
43,273
72,827
69,736
44,612
41,992
57,730
57,332
93,076
135,814
140,872
157,977
Effective Tax Rate (%)
15.79
8.79
20.88
21.44
23.98
27.89
34.64
32.33
12.56
26.72
13.35
25.3
25.8
Profit Margin (%)
32.59
52.15
34.84
40
38.23
21.81
19.9
24.9
20.35
29.11
36.41
33.14
32.94
Working Capital
-2,023
89,626
131,437
656,714
661,763
603,343
624,635
562,054
440,550
510,347
461,846
586,318
663,190
LT Debt
- -
- -
- -
79,572
82,926
89,999
92,322
96,819
1,259
89,915
34,842
751
481
Total Equity
42,674
215,191
273,940
717,920
784,783
744,271
794,069
829,168
849,454
779,678
840,812
980,162
1,087,865
Return on Invested Capital (%)
- -
11.16
19.93
14.7
5.48
5.77
5.92
7.15
9.33
9.23
15.98
15.35
14.69
Return on Capital (%)
- -
22.34
14.52
12.22
7.97
4.87
4.76
6.34
6.04
9.96
14.81
14.37
14.99
Return on Common Equity (%)
- -
27.09
18.79
15.36
9.8
6.25
5.81
7.58
7.31
12.09
17.51
16.06
16.5

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
28,377
28,012
27,830
LT Borrowings
- -
- -
- -
LT Finance Leases
751
548
481
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
2,490,159
2,598,192
2,852,069

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
679,367
724,029
764,448
Cash, Cash Equivalents & STI
538,772
584,656
606,188
Accounts Receivable, Net
74,989
74,339
87,358
Inventories
55,845
55,041
57,141
Total Current Liabilities
93,049
96,605
101,258
Payables & Accruals
- -
- -
- -
ST Debt
28,377
28,012
27,830
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.33%
4.61%
16.57%
Free Cash Flow
57.21%
38.91%
4.14%
Net Income, GAAP
19.85%
29.76%
3.72%
Sales/Revenue/Turnover
22.85%
15.1%
13.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
74,306
95,423
105,109
98,209
373,047
2025
89,820
110,260
105,898
119,131
425,110
2026
116,639
137,903
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,923
3,272
3,667
3,652.12
12,520
2025
2,701
3,331
3,316.67
3,570.17
13,061
2026
3,633.6
4,012
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carrie C. Strom
Full Time Employees
629
Sector
Health technology
Industry
Biotechnology
Address
61-20, Sinbuk-ro Chuncheon-si GA South Korea 24206
IPO Date
Dec 24, 2015
Website
hugel-inc.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Hugel, Inc. develops and manufactures biopharmaceuticals focused on medical aesthetics in South Korea and internationally; the company produces botulinum toxin products under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, Botoshot, and Letybo brands for treatments including eyelid convulsion, glabellar lines, upper limb spasticity, equinus foot deformity, and crow's feet; hyaluronic acid fillers under the Dermalax and The Chaeum brand names; skin boosters and cosmetics under the Wellage brand; and medical devices including lifting threads and products under the BlueRose brand. Hugel operates manufacturing facilities in Chuncheon-si and Seoul, South Korea, with a presence in approximately 70 countries through eight global subsidiaries in the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore; it targets medical professionals and consumers in the aesthetics industry, serving markets across Asia-Pacific, Europe, North America, and the Middle East & North Africa. Founded in 2001 and headquartered in Chuncheon-si, South Korea, Hugel recently achieved record net sales, operating profit, and net income in 2024 driven by growth in botulinum toxin, hyaluronic acid fillers, and cosmetics; it entered the US market through a strategic partnership with BENEV Company Inc. for Letybo commercialization following FDA approval, with full-scale sales launched in 2025; expanded into Brazil and Malaysia with Letybo launches and new partner Derma Dream; and strengthened its position as the only South Korean firm approved in the US, China, and Europe botulinum toxin markets.